SCHEMBL4764222

SCHEMBL4764222

O=C(Nc1ccc(-c2cc(C(=O)O)c3cn[nH]c3n2)s1)Nc1cc(C(F)(F)F)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.39
FLT3 P36888 3/20 0.39
RIPK1 Q13546 2/20 0.39
NTRK1 P04629 2/20 0.39
RET P07949 2/20 0.39
CDK8 P49336 2/20 0.39
NTRK3 Q16288 2/20 0.39
MAPK14 Q16539 2/20 0.39
NTRK2 Q16620 2/20 0.39
LTK P29376 1/20 0.39
AURKB Q96GD4 1/20 0.39
KDR P35968 12/20 0.39
KIT P10721 2/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39
LYN P07948 1/20 0.39
SRC P12931 1/20 0.39
FLT1 P17948 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4721935 0.88 RIPK1 (0.40) PDGFRBFLT3RIPK1NTRK1RET
SCHEMBL4912208 0.85 NPC1 (0.39) PDGFRBFLT3RIPK1NTRK1RET
SCHEMBL4722549 0.84 FLT3 (0.52) PDGFRBFLT3RIPK1NTRK1RET
SCHEMBL4723867 0.82 TEK (0.46) PDGFRBFLT3RIPK1NTRK1RET
SCHEMBL4766324 0.82 KDR (0.40) PDGFRBFLT3RIPK1NTRK1RET
SCHEMBL4872168 0.82 RIPK1 (0.57) FLT3RIPK1KDRKITGRIK1
SCHEMBL1322611 0.82 EPHX2 (0.51) PDGFRBKDRFLT1
SCHEMBL1325609 0.80 KDR (0.41) PDGFRBFLT3RIPK1KDRKIT
SCHEMBL1325879 0.79 RAF1 (0.42) PDGFRBFLT3RIPK1NTRK1RET
SCHEMBL4908646 0.78 NTRK1 (0.41) NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912988-B1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA SA (FR) 2014-04-16 EP claimed
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-31 US claimed
EP-1912988-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF Aventis Pharma S.A. (FR) 2008-04-23 EP claimed
WO-2007017577-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2007-02-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof PRMT7, PRKACA, PRKX PDGFRB 1529/4885FLT3 525/4885RIPK1 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.